CLCM
SAGE

Crawford Lake Capital Management’s Sage Therapeutics SAGE Stock Holding History

Crawford Lake Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-92,300
Closed -$15.2M – 93
2017
Q4 		$15.2M Buy
+92,300
New +$8.95M 3.59% 8

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crawford Lake Capital Management's SAGE Position: Q4 2018 in Review

Crawford Lake Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 21,297 shares — an estimated $3.01M sold.

Crawford Lake Capital Management first reported a position in SAGE in Q4 2017 and held it in 4 quarters. The position peaked at $25.4M in Q4 2017. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • Crawford Lake Capital Management reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 21,297 Sage Therapeutics shares in Q4 2018, an estimated $3.01M.
  • Crawford Lake Capital Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 4 quarters.
  • Crawford Lake Capital Management's Sage Therapeutics position peaked at $25.4M in Q4 2017.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Crawford Lake Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.